<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy - Skoetz, N - 2015 | Cochrane Library</title> <meta content="Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy - Skoetz, N - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007107.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy - Skoetz, N - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007107.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007107.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy" name="citation_title"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Julia Bohlius" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Andreas Engert" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Oliver Blank" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Jörg‐Janne Vehreschild" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD007107.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/12/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007107.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007107.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007107.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols [adverse effects]; Breast Neoplasms [drug therapy]; Febrile Neutropenia [prevention &amp; control]; Fever [prevention &amp; control]; Granulocyte Colony-Stimulating Factor [*therapeutic use]; Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; Infection Control [methods]; Lung Neoplasms [drug therapy]; Neoplasms [drug therapy, mortality]; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007107.pub3&amp;doi=10.1002/14651858.CD007107.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007107\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007107\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007107.pub3",title:"Prophylactic antibiotics or G(M)\\u2010CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy",firstPublishedDate:"Dec 21, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007107.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007107.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007107.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007107.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007107.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007107.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007107.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007107.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007107.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007107.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2581 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007107.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0032"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0033"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/appendices#CD007107-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#CD007107-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#CD007107-cr-0003">Julia Bohlius</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#CD007107-cr-0004">Andreas Engert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#CD007107-cr-0005">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#CD007107-cr-0006">Oliver Blank</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information#CD007107-cr-0007">Jörg‐Janne Vehreschild</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information/en#CD007107-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 December 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007107.pub3">https://doi.org/10.1002/14651858.CD007107.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007107-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007107-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007107-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007107-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD007107-abs-0008">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007107-abs-0001" lang="en"> <section id="CD007107-sec-0001"> <h3 class="title" id="CD007107-sec-0001">Background</h3> <p>Febrile neutropenia (FN) and other infectious complications are some of the most serious treatment‐related toxicities of chemotherapy for cancer, with a mortality rate of 2% to 21%. The two main types of prophylactic regimens are granulocyte (macrophage) colony‐stimulating factors (G(M)‐CSF) and antibiotics, frequently quinolones or cotrimoxazole. Current guidelines recommend the use of colony‐stimulating factors when the risk of febrile neutropenia is above 20%, but they do not mention the use of antibiotics. However, both regimens have been shown to reduce the incidence of infections. Since no systematic review has compared the two regimens, a systematic review was undertaken. </p> </section> <section id="CD007107-sec-0002"> <h3 class="title" id="CD007107-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of G(M)‐CSF compared to antibiotics in cancer patients receiving myelotoxic chemotherapy. </p> </section> <section id="CD007107-sec-0003"> <h3 class="title" id="CD007107-sec-0003">Search methods</h3> <p>We searched <i>The Cochrane Library</i>, MEDLINE, EMBASE, databases of ongoing trials, and conference proceedings of the American Society of Clinical Oncology and the American Society of Hematology (1980 to December 2015). We planned to include both full‐text and abstract publications. Two review authors independently screened search results. </p> </section> <section id="CD007107-sec-0004"> <h3 class="title" id="CD007107-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing prophylaxis with G(M)‐CSF versus antibiotics for the prevention of infection in cancer patients of all ages receiving chemotherapy. All study arms had to receive identical chemotherapy regimes and other supportive care. We included full‐text, abstracts, and unpublished data if sufficient information on study design, participant characteristics, interventions and outcomes was available. We excluded cross‐over trials, quasi‐randomised trials and post‐hoc retrospective trials. </p> </section> <section id="CD007107-sec-0005"> <h3 class="title" id="CD007107-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the results of the search strategies, extracted data, assessed risk of bias, and analysed data according to standard Cochrane methods. We did final interpretation together with an experienced clinician. </p> </section> <section id="CD007107-sec-0006"> <h3 class="title" id="CD007107-sec-0006">Main results</h3> <p>In this updated review, we included no new randomised controlled trials. We included two trials in the review, one with 40 breast cancer patients receiving high‐dose chemotherapy and G‐CSF compared to antibiotics, a second one evaluating 155 patients with small‐cell lung cancer receiving GM‐CSF or antibiotics. </p> <p>We judge the overall risk of bias as high in the G‐CSF trial, as neither patients nor physicians were blinded and not all included patients were analysed as randomised (7 out of 40 patients). We considered the overall risk of bias in the GM‐CSF to be moderate, because of the risk of performance bias (neither patients nor personnel were blinded), but low risk of selection and attrition bias. </p> <p>For the trial comparing G‐CSF to antibiotics, all cause mortality was not reported. There was no evidence of a difference for infection‐related mortality, with zero events in each arm. Microbiologically or clinically documented infections, severe infections, quality of life, and adverse events were not reported. There was no evidence of a difference in frequency of febrile neutropenia (risk ratio (RR) 1.22; 95% confidence interval (CI) 0.53 to 2.84). The quality of the evidence for the two reported outcomes, infection‐related mortality and frequency of febrile neutropenia, was very low, due to the low number of patients evaluated (high imprecision) and the high risk of bias. </p> <p>There was no evidence of a difference in terms of median survival time in the trial comparing GM‐CSF and antibiotics. Two‐year survival times were 6% (0 to 12%) in both arms (high imprecision, low quality of evidence). There were four toxic deaths in the GM‐CSF arm and three in the antibiotics arm (3.8%), without evidence of a difference (RR 1.32; 95% CI 0.30 to 5.69; P = 0.71; low quality of evidence). There were 28% grade III or IV infections in the GM‐CSF arm and 18% in the antibiotics arm, without any evidence of a difference (RR 1.55; 95% CI 0.86 to 2.80; P = 0.15, low quality of evidence). There were 5 episodes out of 360 cycles of grade IV infections in the GM‐CSF arm and 3 episodes out of 334 cycles in the cotrimoxazole arm (0.8%), with no evidence of a difference (RR 1.55; 95% CI 0.37 to 6.42; P = 0.55; low quality of evidence). There was no significant difference between the two arms for non‐haematological toxicities like diarrhoea, stomatitis, infections, neurologic, respiratory, or cardiac adverse events. Grade III and IV thrombopenia occurred significantly more frequently in the GM‐CSF arm (60.8%) compared to the antibiotics arm (28.9%); (RR 2.10; 95% CI 1.41 to 3.12; P = 0.0002; low quality of evidence). Neither infection‐related mortality, incidence of febrile neutropenia, nor quality of life were reported in this trial. </p> </section> <section id="CD007107-sec-0007"> <h3 class="title" id="CD007107-sec-0007">Authors' conclusions</h3> <p>As we only found two small trials with 195 patients altogether, no conclusion for clinical practice is possible. More trials are necessary to assess the benefits and harms of G(M)‐CSF compared to antibiotics for infection prevention in cancer patients receiving chemotherapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007107-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007107-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007107-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007107-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007107-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/th#CD007107-abs-0009">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007107-abs-0002" lang="en"> <h3>Prophylactic antibiotics or G(M)‐CSF for the prevention of infections in cancer patients undergoing chemotherapy </h3> <p><b>Review question</b> </p> <p>We reviewed the existing literature examining the efficacy and safety of granulocyte (macrophage) colony‐stimulating factors (G(M)‐CSF) compared to antibiotics to prevent infections for cancer patients receiving chemotherapy. </p> <p><b>Background</b> </p> <p>Cancer treatment with chemotherapy (anti‐cancer drugs) disrupts the immune system and lowers white blood cell counts. This increases a person's risk of infection. Both G(M)‐CSF and antibiotics can reduce the risk of infection associated with cancer treatments. The review compared the efficacy of antibiotics to G(M)‐CSFs for the prevention of infection. </p> <p><b>Study characteristics</b> </p> <p>We searched several medical databases and identified two randomised controlled trials (RCT) that met our inclusion criteria; no new trials were identified for this review update. One trial included 40 breast cancer patients receiving high‐dose chemotherapy. Eighteen patients received G‐CSF and 22 got antibiotics (ciprofloxacin and amphotericin) to prevent infection. Another trial evaluated GM‐CSF versus antibiotics in patients with small‐cell lung cancer, with 78 patients in the GM‐CSF arm and 77 patients in the antibiotics arm. </p> <p><b>Key results</b> </p> <p>The study that analysed G‐CSF versus antibiotics did not report all cause mortality, microbiologically or clinically documented infections, severe infections, quality of life, or adverse events. We found no evidence of a difference between the two prophylactic options for the outcomes of infection‐related mortality (no patient died because of infection), or febrile neutropenia. </p> <p>The trial that assessed GM‐CSF versus antibiotics did not found any evidence of a difference in all cause mortality, trial mortality, infections, or severe infections. The only difference between the two arms was found for the adverse event thrombocytopenia, favouring patients receiving antibiotics. Quality of life was not reported in this trial. </p> <p>More research is needed to determine the best prevention against infection in cancer patients. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence for infection‐related mortality and frequency of febrile neutropenia in the G‐CSF trial was very low, because of the small number of patients that were evaluated, and the study design (high risk of bias). The trial that analysed GM‐CSF versus antibiotics reported overall survival, toxic deaths, infections, severe infections, and adverse events. Because of the very small number of patients included, we judged that the overall quality for all these outcomes was low. </p> <p>The evidence is current to December 2015.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007107-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007107-sec-0099"></div> <h3 class="title" id="CD007107-sec-0100">Implications for practice</h3> <section id="CD007107-sec-0100"> <p>There is insufficient direct evidence from randomised controlled trials to recommend one prophylaxis (G‐CSFs, GM‐CSFs, or antibiotics) over the other for cancer patients receiving myelotoxic chemotherapy. </p> </section> <h3 class="title" id="CD007107-sec-0101">Implications for research</h3> <section id="CD007107-sec-0101"> <p>Large high quality trials comparing antibiotic prophylaxis to infection prophylaxis using G‐CSFs or GM‐CSFs are necessary in a wide range of cancer patients, to evaluate clinically important outcomes, like all cause and infection‐related mortality, incidence of febrile neutropenia, quality of life and adverse events. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007107-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007107-sec-0022"></div> <div class="table" id="CD007107-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>G‐CSF compared with antibiotics</b> f<b>or the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cancer patients receiving myelotoxic chemotherapy </p> <p><b>Intervention:</b> G‐CSF </p> <p><b>Comparison:</b> antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>G‐CSF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,2</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no patient died of infectious causes during the 18‐week duration of the trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of febrile neutropenia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>318 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>388 per 1000</b> </p> <p>(169 to 904)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.22</b> </p> <p>(0.53 to 2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,2</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of severe infections</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> due to the low number of very low number of events, the result is highly imprecise (downgraded by 2 points) </p> <p><sup>2</sup> high risk of performance bias (neither patients nor physicians blinded) and detection bias (no intention to treat analysis) (downgraded by 1 point) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007107-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GM‐CSF compared with antibiotics</b> f<b>or the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cancer patients receiving myelotoxic chemotherapy </p> <p><b>Intervention:</b> GM‐CSF </p> <p><b>Comparison:</b> antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>GM‐CSF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<sup>1</sup> <br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two‐year survival times were 6% (0 to 12%) in both arms</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of febrile neutropenia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of severe infections</p> <p>(Grade III or IV)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>282 per 1000</b> </p> <p>(156 to 509)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.55</b> </p> <p>(0.86 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<sup>1</sup> <br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>Toxic deaths</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> <p>(12 to 222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> </p> <p>(0.30 to 5.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1</sup> <br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> due to the low number of very low number of events, the result is highly imprecise (downgraded by 2 points) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007107-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007107-sec-0023"></div> <section id="CD007107-sec-0024"> <h3 class="title" id="CD007107-sec-0024">Description of the condition</h3> <p>Cancer patients receiving myelosuppressive therapy or haematopoetic stem cell transplantation are at increased risk of febrile neutropenia and infectious complications. The risk of febrile neutropenia and subsequent infection is directly related to the duration and severity of neutropenia (<a href="./references#CD007107-bbs2-0092" title="BodeyGP , BuckleyM , SatheYS , FreireichEJ . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine1966;64(2):328‐40. ">Bodey 1966</a>; <a href="./references#CD007107-bbs2-0093" title="BodeyGP . Infection in cancer patients. A continuing association. American Journal of Medicine1986;81(1A):11‐26. ">Bodey 1986</a>). Infectious complications constitute major dose‐limiting side effects in patients undergoing myelosuppressive therapy. Special risk circumstances, such as patient age greater than 65 years or poor performance status, impact the associated morbidity and mortality (<a href="./references#CD007107-bbs2-0116" title="KudererNM , DaleDC , CrawfordJ , CoslerLE , LymanGH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006;106(10):2258‐66. ">Kuderer 2006</a>; <a href="./references#CD007107-bbs2-0125" title="PizzoPA . Fever in immunocompromised patients. New England Journal of Medicine1999;341(12):893‐900. ">Pizzo 1999</a>). The mortality rate associated with febrile neutropenia in cancer patients is between 2% and 21% (<a href="./references#CD007107-bbs2-0127" title="SmithTJ , BohlkeK , LymanGH , CarsonKR , CrawfordJ , CrossSJ , et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology2015;33(28):3199‐212. ">Smith 2015</a>). In addition, infectious complications are a common cause of dose reductions during chemotherapy treatment. </p> <p>Febrile neutropenia (FN) can be prevented by a prophylactic regimen. Prophylaxis started at the beginning of the first chemotherapy cycle or in parallel with documented or anticipated neutropenia is called primary prophylaxis, whereas prophylaxis given to patients who had already experienced episodes of FN in an earlier chemotherapy cycle, is referred to as secondary prophylaxis. Effective prophylaxis, using either colony‐stimulating factors (CSF) or antibiotics (or both), would decrease clinically relevant negative outcomes such as all cause mortality, infection‐related mortality, and infectious complications. Given the high costs of the consequences of FN, and also of the colony‐stimulating factors themselves, economic arguments are introduced into discussions on the best prophylactic strategy (<a href="./references#CD007107-bbs2-0116" title="KudererNM , DaleDC , CrawfordJ , CoslerLE , LymanGH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006;106(10):2258‐66. ">Kuderer 2006</a>; <a href="./references#CD007107-bbs2-0118" title="LeiboviciL , PaulM , CullenM , BucaneveG , Gafter‐GviliA , FraserA , et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer2006;107(8):1743‐51. ">Leibovici 2006</a>). </p> <p>In clinical trials addressing the prevention of FN, granulocyte‐macrophage colony‐stimulating factors (GM‐CSFs) have been reported to be effective in reducing the duration and severity of chemotherapy‐induced febrile neutropenia (<a href="./references#CD007107-bbs2-0114" title="JohnstonE , CrawfordJ , BlackwellS , BjurstromT , LockbaumP , RoskosL , et al. Randomized, dose‐escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Journal of Clinical Oncology2000;18(13):2522‐8. ">Johnston 2000</a>; <a href="./references#CD007107-bbs2-0112" title="HolmesFA , JonesSE , O'ShaughnessyJ , VukeljaS , GeorgeT , SavinM , et al. Comparable efficacy and safety profiles of once‐per‐cycle pegfilgrastim and daily injection filgrastim in chemotherapy‐induced neutropenia: a multicenter dose‐finding study in women with breast cancer. Annals of Oncology2002;13(6):903‐9. ">Holmes 2002</a>). Prophylaxis, using antibiotics, has also been shown to be beneficial with reduced fever, incidence of infections and hospitalisations (<a href="./references#CD007107-bbs2-0096" title="BucaneveG , MicozziA , MenichettiF , MartinoP , DionisiMS , MartinelliG , et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine2005;353(10):977‐87. ">Bucaneve 2005</a>; <a href="./references#CD007107-bbs2-0018" title="CullenM , StevenN , BillinghamL , GauntC , HastingsM , SimmondsP , et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine2005;353(10):988‐98. ">Cullen 2005</a>). </p> </section> <section id="CD007107-sec-0025"> <h3 class="title" id="CD007107-sec-0025">Description of the intervention</h3> <section id="CD007107-sec-0026"> <h4 class="title">Colony‐stimulating factors (CSF)</h4> <p>The current American Society of Clinical Oncology (ASCO) guidelines justify the administration of CSFs in clinical settings where the expected risk of suffering FN is approximately 20% (<a href="./references#CD007107-bbs2-0127" title="SmithTJ , BohlkeK , LymanGH , CarsonKR , CrawfordJ , CrossSJ , et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology2015;33(28):3199‐212. ">Smith 2015</a>). In addition to the myelotoxicity of the planned chemotherapy regimen, patient‐specific risk factors should be taken into account. Secondary prophylaxis with CSFs is recommended for patients who have developed a neutropenic complication in a previous chemotherapy cycle, and in whom a reduced dose might compromise disease‐free or overall survival, or treatment outcome. The guidelines from the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) give similar recommendations (<a href="./references#CD007107-bbs2-0133" title="VehreschildJJ , BohmeA , CornelyOA , KahlC , KarthausM , KreuzerKA , et al. Prophylaxis of infectious complications with colony‐stimulating factors in adult cancer patients undergoing chemotherapy‐evidence‐based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Annals of Oncology2014;25(9):1709‐18. [PUBMED: 24631945] ">Vehreschild 2014</a>). </p> <p>Thus far, randomised controlled trials (<a href="./references#CD007107-bbs2-0099" title="CrawfordJ , OzerH , StollerR , JohnsonD , LymanG , TabbaraI , et al. Reduction by granulocyte colony‐stimulating factor of fever and neutropenia induced by chemotherapy in patients with small‐cell lung cancer. New England Journal of Medicine1991;325(3):164‐70. ">Crawford 1991</a>; <a href="./references#CD007107-bbs2-0082" title="Trillet‐LenoirV , GreenJ , ManegoldC , VonPawelJ , GatzemeierU , LebeauB , et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer1993;29A(3):319‐24. ">Trillet‐Lenoir 1993</a>), and subsequent meta‐analyses, have shown that primary prophylaxis with CSFs is effective in reducing FNin patients with both solid and haematological malignancies (<a href="./references#CD007107-bbs2-0094" title="BohliusJ , HerbstC , ReiserM , SchwarzerG , EngertA . Granulopoiesis‐stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003189.pub4] ">Bohlius 2008</a>; <a href="./references#CD007107-bbs2-0108" title="HackshawA , SweetenhamJ , KnightA . Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non‐Hodgkin's lymphoma?. British Journal of Cancer2004;90(7):1302‐5. ">Hackshaw 2004</a>; <a href="./references#CD007107-bbs2-0120" title="LymanGH , KudererNM , DjulbegovicB . Prophylactic granulocyte colony‐stimulating factor in patients receiving dose‐intensive cancer chemotherapy: A meta‐analysis. American Journal of Medicine2002;112(5):406‐11. ">Lyman 2002</a>; <a href="./references#CD007107-bbs2-0130" title="SungL , NathanPC , LangeB , BeyeneJ , BuchananJR . Prophylactic granulocyte colony‐stimulating factor and granulocyte‐macrophage colony‐stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta‐analysis of randomized controlled trials. Journal of Clinical Oncology2004;22(16):3350‐6. ">Sung 2004</a>; <a href="./references#CD007107-bbs2-0131" title="SungL , NathanPC , AlibhaiSM , TomlinsonGA , BeyeneJ . Meta‐analysis: effect of prophylactic hematopoietic colony‐stimulating factors on mortality and outcomes of infection. Annals of Internal Medicine2007;147(6):400‐11. ">Sung 2007</a>; <a href="./references#CD007107-bbs2-0134" title="WittmanB , HoranJ , LymanGH . Prophylactic colony‐stimulating factors in children receiving myelosuppressive chemotherapy: a meta‐analysis of randomized controlled trials. Cancer Treatment Reviews2006;32(4):289‐303. ">Wittman 2006</a>). Furthermore, GM‐CSFs may decrease hospitalisation and the use of intravenous therapeutic antibiotics (<a href="./references#CD007107-bbs2-0099" title="CrawfordJ , OzerH , StollerR , JohnsonD , LymanG , TabbaraI , et al. Reduction by granulocyte colony‐stimulating factor of fever and neutropenia induced by chemotherapy in patients with small‐cell lung cancer. New England Journal of Medicine1991;325(3):164‐70. ">Crawford 1991</a>; <a href="./references#CD007107-bbs2-0082" title="Trillet‐LenoirV , GreenJ , ManegoldC , VonPawelJ , GatzemeierU , LebeauB , et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer1993;29A(3):319‐24. ">Trillet‐Lenoir 1993</a>). In a meta‐analysis on the use of G‐CSFs in cancer patients hospitalised with established FN, the authors observed a possible benefit of adding GM‐CSFs to antibiotic treatment on infection‐related mortality and length of hospitalisation(<a href="./references#CD007107-bbs2-0098" title="ClarkOA , LymanGH , CastroAA , ClarkLG , DjulbegovicB . Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia: a meta‐analysis of randomized controlled trials. Journal of Clinical Oncology2005;23(18):4198‐214. ">Clark 2005</a>). A meta‐analysis by <a href="./references#CD007107-bbs2-0116" title="KudererNM , DaleDC , CrawfordJ , CoslerLE , LymanGH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006;106(10):2258‐66. ">Kuderer 2006</a> showed that under certain standard dose chemotherapy regimens, early and infection‐related mortality were also reduced with primary G‐CSF prophylaxis. However, none of the meta‐analyses with less restrictive inclusion criteria were able to demonstrate that prophylactic administration of GM‐CSFs improved overall survival when compared to placebo or no treatment. None of these analyses addressed the question of GM‐CSFs versus antibiotics, which is a question closer to clinical reality. One group did a subgroup analysis of studies in which the published report mandated antibiotic prophylaxis compared to those that did not, and found no difference between the groups (<a href="./references#CD007107-bbs2-0131" title="SungL , NathanPC , AlibhaiSM , TomlinsonGA , BeyeneJ . Meta‐analysis: effect of prophylactic hematopoietic colony‐stimulating factors on mortality and outcomes of infection. Annals of Internal Medicine2007;147(6):400‐11. ">Sung 2007</a>). This may be due to the high number of trials where no information about antibiotic prophylaxis use is available. In addition, this meta‐analysis included studies that analysed cycles of chemotherapy as opposed to patients. The distorting effect of such an analysis is difficult to estimate. </p> <p>Of the many meta‐analyses looking at GM‐CSF versus placebo or no treatment, only one meta‐analysis, restricted to patients with lymphoma, was published in <i>The Cochrane Library</i> (<a href="./references#CD007107-bbs2-0094" title="BohliusJ , HerbstC , ReiserM , SchwarzerG , EngertA . Granulopoiesis‐stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003189.pub4] ">Bohlius 2008</a>). This analysis found a reduction in the rate of infections (odds ratio (OR) 0.74; 95% CI 0.64 to 0.85) but no effect on infection‐related mortality (OR 1.37 favouring control; 95% CI 0.66 to 2.82). </p> <p>GM‐CSF is usually well tolerated, with only a moderate number of adverse events, mostly bone pain and headaches, however, there are some hints of increased risk of acute myeloid leukaemia or myelodysplastic syndromes (<a href="./references#CD007107-bbs2-0121" title="LymanGH , DaleDC , WolffDA , CulakovaE , PoniewierskiMS , KudererNM , et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony‐stimulating factor: a systematic review. Journal of Clinical Oncology2010;28(17):2914‐24. [PUBMED: 20385991] ">Lyman 2010</a>). </p> </section> <section id="CD007107-sec-0027"> <h4 class="title">Antibiotics</h4> <p>During the last decade, prophylaxis with antibiotics was studied in a number of randomised clinical trials. The evidence provided was not considered to be entirely convincing, because none of the studies were sufficiently large to provide conclusive evidence on the real efficacy of prophylaxis (<a href="./references#CD007107-bbs2-0096" title="BucaneveG , MicozziA , MenichettiF , MartinoP , DionisiMS , MartinelliG , et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine2005;353(10):977‐87. ">Bucaneve 2005</a>; <a href="./references#CD007107-bbs2-0018" title="CullenM , StevenN , BillinghamL , GauntC , HastingsM , SimmondsP , et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine2005;353(10):988‐98. ">Cullen 2005</a>; <a href="./references#CD007107-bbs2-0115" title="KarpJE , MerzWG , HendricksenC , LaughonB , ReddenT , BambergerBJ , et al. Oral norfloxacin for prevention of gram‐negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine1987;106(1):1‐7. ">Karp 1987</a>; <a href="./references#CD007107-bbs2-0119" title="LewMA , KehoeK , RitzJ , AntmanKH , NadlerL , KalishLA , et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. Journal of Clinical Oncology1995;13(1):239‐50. ">Lew 1995</a>). Subsequent meta‐analyses suggested that prophylaxis using antibiotics reduced the incidence of gram‐negative bacterial infection, total infection, fever episodes, and hospitalisation (<a href="./references#CD007107-bbs2-0100" title="CrucianiM , MalenaM , BoscoO , NardiS , SerpelloniG , MengoliC . Reappraisal with meta‐analysis of the addition of Gram‐positive prophylaxis to fluoroquinolone in neutropenic patients. Journal of Clinical Oncology2003;21(22):4127‐37. ">Cruciani 2003</a>; <a href="./references#CD007107-bbs2-0102" title="EngelsEA , LauJ , BarzaM . Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta‐analysis. Journal of Clinical Oncology1998;16(3):1179‐87. ">Engels 1998</a>). Moreover, a meta‐analysis of data on antibiotic prophylaxis (or more specifically, fluoroquinolones) compared to placebo or no intervention demonstrated that not only infections were reduced, but all cause mortality, and infection‐related mortality were too (<a href="./references#CD007107-bbs2-0104" title="Gafter‐GviliA , FraserA , PaulM , LeiboviciL . Meta‐Analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of Internal Medicine2005;142(12 Pt 1):979‐95. ">Gafter‐Gvili 2005</a>; <a href="./references#CD007107-bbs2-0106" title="Gafter‐GviliA , FraserA , PaulM , VidalL , LawrieTA , van deWeteringM D , et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD004386.pub3] ">Gafter‐Gvili 2012</a>; <a href="./references#CD007107-bbs2-0118" title="LeiboviciL , PaulM , CullenM , BucaneveG , Gafter‐GviliA , FraserA , et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer2006;107(8):1743‐51. ">Leibovici 2006</a>). One important question which is still unanswered is whether prophylaxis should be considered for all patients with cancer and neutropenia. In another meta‐analysis on antibiotic prophylaxis, the majority of patients were suffering from haematological malignancies and received high‐dose chemotherapy and bone marrow transplantation, with only a few studies focusing on solid tumours (<a href="./references#CD007107-bbs2-0018" title="CullenM , StevenN , BillinghamL , GauntC , HastingsM , SimmondsP , et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine2005;353(10):988‐98. ">Cullen 2005</a>; <a href="./references#CD007107-bbs2-0106" title="Gafter‐GviliA , FraserA , PaulM , VidalL , LawrieTA , van deWeteringM D , et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD004386.pub3] ">Gafter‐Gvili 2012</a>). Another factor possibly compromising the results of the main meta‐analysis was that studies were included that randomised chemotherapy cycles and not patients, or reported cycle‐based outcomes, as opposed to a true incidence (where the number of patients and not cycles are analysed). No information on GM‐CSFs compared to antibiotics was available from these analyses. </p> </section> </section> <section id="CD007107-sec-0028"> <h3 class="title" id="CD007107-sec-0028">How the intervention might work</h3> <section id="CD007107-sec-0029"> <h4 class="title">Colony‐stimulating factors</h4> <p>Granulocyte colony‐stimulating factors (G‐CSF) predominantly augment the proliferation, maturation, and release of neutrophils, resulting in a dose‐dependent increase in circulating neutrophils (<a href="./references#CD007107-bbs2-0095" title="BronchudMH , PotterMR , MorgensternG , BlascoMJ , ScarffeJH , ThatcherN , et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony‐stimulating factor in patients. British Journal of Cancer1988;58(1):64‐9. ">Bronchud 1988</a>; <a href="./references#CD007107-bbs2-0123" title="MorstynG , CampbellL , SouzaLM , AltonNK , KeechJ , GreenM , et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet1988;1(8587):667‐72. ">Morstyn 1988</a>). It is a growth factor for the myeloid lineage that stimulates the growth of granulocytes and eosinophil colonies; granulocyte (macrophage) colony‐stimulating factors (GM‐CSF) also stimulate the growth of macrophages (<a href="./references#CD007107-bbs2-0107" title="GriffinJD , CannistraSA , SullivanR , DemetriGD , ErnstTJ , KanakuraY . The biology of GM‐CSF: regulation of production and interaction with its receptor. International Journal of Cell Cloning1990;8 Suppl 1:35‐44. ">Griffin 1990</a>). Both colony‐stimulating factors have shown comparable results in decreasing the incidence and duration of neutropenia and fever after chemotherapy. However, there is a lack of formal comparisons between the two drugs. Probably due to the macrophage activation caused by GM‐CSF, but not G‐CSF, tolerability of GM‐CSF has been reported to be inferior. Injection site reactions in particular, seem more frequent with GM‐CSF (<a href="./references#CD007107-bbs2-0089" title="Alvarado IbarraML , Borbolla EscobozaJR , Lopez‐HernandezMA , Gonzalez‐AvanteCM , FloresChapaJD , Trueba ChristyE , et al. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM‐CSF. Revista de Investigacion Clinica1999;51(2):77‐80. [PUBMED: 10410585] ">Alvarado 1999</a>; <a href="./references#CD007107-bbs2-0090" title="BeveridgeRA , MillerJA , KalesAN , BinderRA , RobertNJ , Heisrath‐EvansJ , et al. Randomized trial comparing the tolerability of sargramostim (yeast‐derived RhuGM‐CSF) and filgrastim (bacteria‐derived RhuG‐CSF) in cancer patients receiving myelosuppressive chemotherapy. Supportive Care in Cancer1997;5(4):289‐98. [PUBMED: 9257425] ">Beveridge 1997</a>; <a href="./references#CD007107-bbs2-0091" title="BeveridgeRA , MillerJA , KalesAN , BinderRA , RobertNJ , HarveyJH , et al. A comparison of efficacy of sargramostim (yeast‐derived RhuGM‐CSF) and filgrastim (bacteria‐derived RhuG‐CSF) in the therapeutic setting of chemotherapy‐induced myelosuppression. Cancer Investigation1998;16(6):366‐73. [PUBMED: 9679526] ">Beveridge 1998</a>; <a href="./references#CD007107-bbs2-0103" title="FischmeisterG , KurzM , HaasOA , MickscheM , BuchingerP , PrintzD , et al. G‐CSF versus GM‐CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Annals of Hematology1999;78(3):117‐23. [PUBMED: 10211753] ">Fischmeister 1999</a>; <a href="./references#CD007107-bbs2-0113" title="HovgaardDJ , NissenNI . Effect of recombinant human granulocyte‐macrophage colony‐stimulating factor in patients with Hodgkin's disease: a phase I/II study. Journal of Clinical Oncology1992;10(3):390‐7. [PUBMED: 1740678] ">Hovgaard 1992</a>). Given the undesired additional effects of GM‐CSF and concerns of tumour stimulation by GM‐CSF, the drug has become more or less disregarded by recent clinical studies and guidelines (<a href="./references#CD007107-bbs2-0127" title="SmithTJ , BohlkeK , LymanGH , CarsonKR , CrawfordJ , CrossSJ , et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology2015;33(28):3199‐212. ">Smith 2015</a>). Granulocyte (macrophage) colony‐stimulating factors is no longer commercially available in several European countries for infection prophylaxis. It is licensed for mobilisation of stem cells, and after autologous or allogeneic stem cell transplantation (<a href="./references#CD007107-bbs2-0127" title="SmithTJ , BohlkeK , LymanGH , CarsonKR , CrawfordJ , CrossSJ , et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology2015;33(28):3199‐212. ">Smith 2015</a>). </p> </section> <section id="CD007107-sec-0030"> <h4 class="title">Antibiotics</h4> <p>Antibiotic prophylaxis, most often using flouroquinolones, reduces infections by targeting potential pathogens, and in contrast to G‐CSFs it does not provoke the dose‐limiting effect of haematological toxicity. A major concern of a routine prophylactic use of antibiotics in patients with cancer and neutropenia is that it increases bacterial resistance to these agents. This, in turn, may compromise the treatment success of both current and future serious infections by expanding (multi)resistance. In addition, hypersensitivity reactions, gastrointestinal toxicities, and the promotion of fungal overgrowth after antibiotics put the patient at risk of potentially serious adverse events. These factors may limit their efficacy in reducing infection‐related morbidity or mortality (<a href="./references#CD007107-bbs2-0097" title="CarratalaJ , Fernandez‐SevillaA , TubauF , CallisM , GudiolF . Emergence of quinolone‐resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clinical Infectious Diseases1995;20(3):557‐60. ">Carratala 1995</a>; <a href="./references#CD007107-bbs2-0105" title="Gafter‐GviliA , PaulM , FraserA , LeiboviciL . Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta‐analysis. Journal of Antimicrobial Chemotherapy2007;59(1):5‐22. ">Gafter‐Gvili 2007</a>; <a href="./references#CD007107-bbs2-0128" title="SomolinosN , ArranzR , DelReyMC , JimenezML . Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. Journal of Antimicrobial Chemotherapy1992;30(5):730‐1. ">Somolinos 1992</a>). </p> </section> </section> <section id="CD007107-sec-0031"> <h3 class="title" id="CD007107-sec-0031">Why it is important to do this review</h3> <p>The best prophylactic treatment of febrile neutropenia and infections in cancer patients receiving antineoplastic therapy remains controversial, and in general, international guidelines concentrate on either antibiotics or G‐CSFs. The evidence outlined above suggests that prophylaxis with an antibiotic might be as effective as with G‐CSFs for reducing both infections and mortality. </p> <p>The aim of this systematic review is to provide a comprehensive overview on the benefits and harms of G‐CSF compared to antibiotics for infection prophylaxis in cancer patients. By systematically identifying all randomised trials conducted to date and by conducting a critical review of their reliability and validity, we will mitigate the statistical limitations of individual studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007107-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007107-sec-0032"></div> <p>To compare the efficacy and safety of G‐CSF or GM‐CSF compared to antibiotics in cancer patients receiving myelotoxic chemotherapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007107-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007107-sec-0033"></div> <section id="CD007107-sec-0034"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007107-sec-0035"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs). We excluded cross‐over trials and quasi‐randomised trials. We included full‐text, abstracts, and unpublished data if sufficient information on study design, participant characteristics, interventions and outcomes was available. </p> </section> <section id="CD007107-sec-0036"> <h4 class="title">Types of participants</h4> <p>We planned to include paediatric and adult, male and female patients with a confirmed diagnosis of any type of cancer who were undergoing myelotoxic chemotherapy. Both solid and haematological malignancies were eligible. </p> </section> <section id="CD007107-sec-0037"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing G‐CSF or GM‐CSF to antibiotics in the primary prophylaxis of infection‐related complications. Trials that examined pegylated G‐CSF (pegfilgrastim) were eligible, provided pegfilgrastim was given once, 24 hours after the completion of chemotherapy. </p> <p>Comparison 1</p> <p> <ul id="CD007107-list-0001"> <li> <p>G‐CSF versus antibiotics</p> </li> </ul> </p> <p>Comparison 2</p> <p> <ul id="CD007107-list-0002"> <li> <p>GM‐CSF versus antibiotics</p> </li> </ul> </p> <p>Trials looking at secondary prophylaxis, defined as prophylaxis in a patient who suffered from FN in an earlier course of chemotherapy, were also eligible, but a subgroup analysis was planned. However, we did not identify any trial evaluating secondary prophylaxis. </p> <p>We included studies in which the intended chemotherapy regimen and supportive care did not differ between study arms. Therefore, we excluded studies that compared dose‐intensified, dose‐accelerated, or dose‐dense regimens with standard chemotherapy, as this resulted in different chemotherapy protocols in the arm that received antibiotic prophylaxis and the arm that received CSF prophylaxis. Trials with more than two arms were included, provided at least two arms with the relevant comparison had the same chemotherapy protocol. </p> <p>We excluded trials using G‐CSF, GM‐CSF, or antibiotics to treat febrile neutropenia, fever, or infections. </p> </section> <section id="CD007107-sec-0038"> <h4 class="title">Types of outcome measures</h4> <section id="CD007107-sec-0039"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007107-list-0003"> <li> <p>Overall survival</p> </li> <li> <p>All cause mortality (including infection‐related, treatment‐related, or on‐trial mortality)</p> </li> <li> <p>Infection‐related mortality</p> </li> </ul> </p> <p>Studies focusing solely on the efficacy of prophylaxis will most likely have short‐term follow‐up only, mainly providing information on early mortality. Determining the cause of death in severely ill patients can be associated with measurement bias. Therefore, we extracted all cause mortality, comprising infection‐related and treatment‐related mortality. </p> </section> <section id="CD007107-sec-0040"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007107-list-0004"> <li> <p>Microbiologically or clinically documented infections, or both</p> <ul id="CD007107-list-0005"> <li> <p>We accepted any definition of clinically documented or microbiologically documented infections given by authors. If available, we extracted data on all, not only severe, clinically or microbiologically documented infections. Microbiologically documented infections were required to have some kind of cultural confirmation of the infection. Infections reported without information on microbiological confirmation were considered to be clinically documented infections. </p> </li> </ul> </li> <li> <p>Severe infections</p> </li> <li> <p>Frequency of febrile neutropenia (FN; any definition of fever and neutropenia accepted)</p> </li> <li> <p>Quality of life (QoL; if measured with a validated QoL instrument)</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD007107-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <p>For this updated review, we revised the search strategy used for the first review. We used search strategies based on those described in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007107-bbs2-0117" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, Available from www.cochrane‐handbook.org. 2011. ">Lefebvre 2011</a>)<i>.</i> We did not use any language constraints. </p> <section id="CD007107-sec-0042"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD007107-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; <i>The Cochrane Library</i>, December 2015; see <a href="./appendices#CD007107-sec-0104">Appendix 1</a>) </p> </li> <li> <p>MEDLINE (1980 to December 2015; for search strategy see <a href="./appendices#CD007107-sec-0105">Appendix 2</a>) </p> </li> <li> <p>EMBASE (1980 to January 2008; for search strategy see <a href="./appendices#CD007107-sec-0106">Appendix 3</a>) </p> </li> </ul> </p> <p>Since we revised our searches, we re‐ran them for CENTRAL and MEDLINE for the entire period, i.e. 1980 to 2015. </p> </section> <section id="CD007107-sec-0043"> <h4 class="title">Searching other resources</h4> <p>We searched conference proceedings of the following annual meetings, which were not included in CENTRAL for abstracts: </p> <p> <ul id="CD007107-list-0007"> <li> <p>American Society of Hematology (ASH) from 2000 to 2015</p> </li> <li> <p>American Society of Clinical Oncology (ASCO) from 2000 to 2015</p> </li> <li> <p>European Hematology Association (EHA) from 2000 to 2015</p> </li> </ul> </p> <p>We electronically searched the database of ongoing trials:</p> <p> <ul id="CD007107-list-0008"> <li> <p><a href="http://www.controlled-trials.com/mrct/" target="_blank">Metaregister of controlled trials</a> </p> </li> </ul> </p> <p>We handsearched the following references:</p> <p> <ul id="CD007107-list-0009"> <li> <p>References of all identified trials, relevant review articles and current treatment guidelines </p> </li> </ul> </p> </section> </section> <section id="CD007107-sec-0044"> <h3 class="title" id="CD007107-sec-0044">Data collection and analysis</h3> <section id="CD007107-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NS, OB) independently screened the results of the search strategies for eligibility by reading the abstracts. In the case of disagreement, we obtained the full‐text publication. If no consensus could be reached, we consulted a third review author, in accordance with Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007107-bbs2-0109" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. 2011. ">Higgins 2011</a>). </p> <p>We documented the study selection process in a flow chart as recommended in the PRISMA statement (<a href="./references#CD007107-bbs2-0122" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐Analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>), showing the total numbers of retrieved references and the numbers of included and excluded studies. </p> </section> <section id="CD007107-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted the data according to the guidelines proposed by <a href="./references#CD007107-bbs2-0111" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].The Cochrane Collaboration. Available from www.cochrane‐handbook.org. 2011. ">Higgins 2011b</a>. If required, we contacted authors of individual studies for additional information. We used a standardised data extraction form containing the following items: </p> <p> <ul id="CD007107-list-0010"> <li> <p>General information: author; title; source; publication date; country; language; duplicate publications. </p> </li> <li> <p>Quality assessment ('Risk of bias' assessment): sequence generation; allocation concealment; blinding (participants, personnel, outcome assessors); incomplete outcome data; selective outcome reporting; other potential sources of bias. </p> </li> <li> <p>Study characteristics: trial design; aims; setting and dates; source of participants; inclusion and exclusion criteria; comparability of groups; subgroup analysis; statistical methods; power calculations; treatment cross‐overs; compliance with assigned treatment; length of follow‐up; time point of randomisation. </p> </li> <li> <p>Participant characteristics: age; diagnosis; stage of disease; prior treatments; number of participants recruited, allocated, and evaluated; participants lost to follow‐up; noticeable differences in risk factors for developing FN. </p> </li> <li> <p>Interventions: duration; type; dose and timing of GM‐CSF, G‐CSF, antibiotics, and other infection prophylaxes (e.g. antimycotics); concomitant treatment (setting, duration, type of chemotherapy); and supportive care (e.g. type of empirical antibiotic therapy). </p> </li> <li> <p>Outcomes: all cause mortality; infection‐related mortality; microbiologically or clinically documented infections, or both; severe infections; QoL; frequency of FN; adverse events. </p> </li> </ul> </p> </section> <section id="CD007107-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NS and OB) independently assessed the risk of bias for each study using the following criteria outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>(<a href="./references#CD007107-bbs2-0110" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. 2011. ">Higgins 2011a</a>). </p> <p> <ul id="CD007107-list-0011"> <li> <p>Sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding (participants, personnel, outcome assessors)</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ul> </p> <p>We made a judgement for every criterion, using one of three categories.</p> <p> <ol id="CD007107-list-0012"> <li> <p>'Low risk': if the criterion was adequately fulfilled in the study, i.e. the study was at a low risk of bias for the given criterion. </p> </li> <li> <p>'High risk': if the criterion was not fulfilled in the study, i.e. the study was at high risk of bias for the given criterion. </p> </li> <li> <p>'Unclear': if the study report did not provide sufficient information to allow for a judgement of 'Yes' or 'No', or if the risk of bias was unknown for one of the criteria listed above. </p> </li> </ol> </p> </section> <section id="CD007107-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>We used intention‐to‐treat data. For binary outcomes, we calculated risk ratios (RRs) with 95% confidence intervals (CIs) for each comparison. We did not identify or extract time‐to‐event or continuous outcomes. </p> </section> <section id="CD007107-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>We evaluated the number of patients with events rather than number of episodes, as the second one could be biased (e.g. a patient with one episode of febrile neutropenia is at increased risk to have a second episode of febrile neutropenia). </p> </section> <section id="CD007107-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>As suggested in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007107-bbs2-0111" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].The Cochrane Collaboration. Available from www.cochrane‐handbook.org. 2011. ">Higgins 2011b</a>), there were many potential sources of missing data that had to be taken into account: at the study level, outcome level, and summary data level. It is important to distinguish between 'missing at random' and 'not missing at random'. As we only identified one trial without missing data, we did not contact the original investigators. </p> </section> <section id="CD007107-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>As we only found two trials, which we did not meta‐analyse, we did not assess heterogeneity of treatment effects between trials. </p> </section> <section id="CD007107-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>In meta‐analyses with at least 10 trials included for one outcome, we would have explored potential publication bias by generating a funnel plot and statistically testing this by using a linear regression test (<a href="./references#CD007107-bbs2-0129" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, Available from www.cochrane‐handbook.org.. 2011. ">Sterne 2011</a>). We would have considered a P value of less than 0.1 to be significant for this test. However, as we analysed two trials only, we did not generate a funnel plot. </p> </section> <section id="CD007107-sec-0053"> <h4 class="title">Data synthesis</h4> <p>As we only identified one trial for each comparison, we could not pool data. However, to analyse data for individual studies we entered data into <a href="./references#CD007107-bbs2-0126" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager (RevMan)</a> 5.3. </p> <p>Moreoever, we created 'Summary of findings' tables for each comparison on absolute risks in each group with the help of the GRADE approach, and will use it to summarise the evidence of all cause mortality, infection‐related mortality, quality of life, incidence of febrile neutropenia, incidence of severe infections and adverse events. </p> </section> <section id="CD007107-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had considered performing subgroup analyses using the following characteristics:</p> <p> <ul id="CD007107-list-0013"> <li> <p>Different types of underlying malignant disease;</p> </li> <li> <p>Different baseline risk for febrile neutropenia or infection;</p> </li> <li> <p>Study setting (in‐patients or out‐patients);</p> </li> <li> <p>Different type of treatment (e.g. haematologic stem cell transplantation versus standard chemotherapy); </p> </li> <li> <p>Different types of G‐CSFs used;</p> </li> <li> <p>Age (&lt;18 versus ≥ 18 years); and</p> </li> <li> <p>According to whether regimens included antimycotic prophylaxis.</p> </li> </ul> </p> <p>However, as we had insufficient data to meta‐analyse, we could not perform these analyses.</p> </section> <section id="CD007107-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We had considered performing sensitivity analyses using the following quality criteria:</p> <p> <ul id="CD007107-list-0014"> <li> <p>Quality components with regard to low and high risk of bias;</p> </li> <li> <p>Fixed‐effect modelling versus random‐effects modelling;</p> </li> <li> <p>Duration of study; and</p> </li> <li> <p>full‐text publication versus abstract publication only.</p> </li> </ul> </p> <p>Again, as we identified only two trials, which were too heterogenous to pool, we could not perform these analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007107-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007107-sec-0056"></div> <section id="CD007107-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD007107-sec-0058"> <h4 class="title">Results of the search</h4> <p>The literature search was designed to find all relevant articles where G‐CSFs, GM‐CSFs, or antibiotics were used as prophylactic agents. For this update, we set up a new search covering all time periods, i.e. after removing duplicates, we screened titles and abstracts of 11,785 references and excluded 11,696 at the initial stage. We assessed the full text of the remaining 89 references and excluded 87 references with reasons (see <a href="#CD007107-sec-0067">Excluded studies</a>). As we identified no new trial fitting the inclusion criteria for this review update, we included the two already known trials in this review. See <a href="#CD007107-fig-0001">Figure 1</a> for study flow diagram. </p> <div class="figure" id="CD007107-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007107-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007107-sec-0059"> <h4 class="title">Included studies</h4> <p>Two studies fulfilled the inclusion criteria of this review. One study involved adults with breast cancer receiving high‐dose chemotherapy, and compared prophylaxis for at least six cycles (<a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a>). The other trial evaluated patients with small‐cell lung cancer receiving accelerated chemotherapy (<a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a>). For more details see <a href="./references#CD007107-sec-0119" title="">Characteristics of included studies</a>. </p> <section id="CD007107-sec-0060"> <h5 class="title">Design</h5> <p><a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> was an open‐label randomised (1:1) study. <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> was a three‐arm trial, two arms of which could be analysed in this review. The third arm evaluated standard chemotherapy without any infectious prophylaxis. </p> </section> <section id="CD007107-sec-0061"> <h5 class="title">Sample sizes</h5> <p><a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> included 40 patients, 18 in the G‐CSF prophylaxis arm and 22 in the antibiotics arm. <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> included 243 patients, 233 of whom were eligible. However, 78 of these patients received an intervention not applicable for this review, therefore 155 patients were analysed in this review. </p> </section> <section id="CD007107-sec-0062"> <h5 class="title">Locations</h5> <p>Location is not reported by <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a>, the <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> trial took place in several European countries. </p> </section> <section id="CD007107-sec-0063"> <h5 class="title">Participants</h5> <p><a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> randomised chemotherapy‐naive patients with breast cancer who received three, three‐week courses of intravenous cyclophosphamide (1500 mg/m²), epirubicin (80 mg/m²), and 5‐fluouracil (1500 or 1000 mg/m²) given on day one; followed by three cycles of intravenous cyclophosphamide (1500 mg/m²), 5‐fluouracil (600 mg/m²) on day one and intravenous methotrexate (1500 mg/m²) on day two. <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> included patients with small‐cell lung cancer receiving six courses of EVI (epirubicin 90 mg/m², vindesine 3 mg/m² and ifosfamide 5 g/m²) every 14 days. </p> </section> <section id="CD007107-sec-0064"> <h5 class="title">Interventions</h5> <p>In the G‐CSF arm in the <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> trial, patients received 263 µg subcutaneous of G‐CSF (lenograstim) on days 3 through to day 12 of each cycle. Patients in the antibiotics arm received two oral prophylactic agents, a combination of ciprofloxacin (250 mg twice daily) and amphotericin B (500 mg four times per day) on days 3 through to day 17 of each cycle, without blinding of the study participants. Patients in the <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> study received either GM‐CSF as a daily subcutaneous dose of 5 µg/kg, from day 3 through to day 13 or until the neutrophil count reached ≥ 4000 mm³ after nadir, or cotrimoxazole (160 mg trimethoprim plus 800 mg sulfamethoxazole). This was administered orally every 12 hours from day three until the end of the courses of chemotherapy. </p> </section> <section id="CD007107-sec-0065"> <h5 class="title">Outcomes</h5> <p><a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> evaluated infection‐related mortality, episodes of hospitalisation for febrile neutropenia, duration of hospitalisation for febrile neutropenia, grade IV leucopenia, and analysed costs of prophylaxis. <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> assessed overall survival, tumour response, absolute and relative dose intensity, incidence of infections and severe infection, and adverse events. None of the trials evaluated quality of life. </p> </section> <section id="CD007107-sec-0066"> <h5 class="title">Conflict of interest</h5> <p>Funding not reported.</p> </section> </section> <section id="CD007107-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 87 trials with reasons (one trial included two comparisons (<a href="./references#CD007107-bbs2-0080" title="Tjan‐HeijnenVC , CaleoS , PostmusPE , ArdizzoniA , BurghoutsJT , BuccholzE , et al. Economic evaluation of antibiotic prophylaxis in small‐cell lung cancer patients receiving chemotherapy: an EORTC double‐blind placebo‐controlled phase III study (08923). Annals of Oncology2003;14(2):248‐57. ">Tjan‐Heijnen 2003</a>): </p> <p> <ul id="CD007107-list-0015"> <li> <p>14 trials compared antibiotics to placebo or no further treatment (<a href="./references#CD007107-bbs2-0007" title="AttalM , SchlaiferD , RubieH , HuguetF , CharletJP , BloomE , et al. Prevention of gram‐positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. Journal of Clinical Oncology1991;9(5):865‐70. ">Attal 1991</a>; <a href="./references#CD007107-bbs2-0014" title="CarlsonJW , FowlerJM , MitchellSK , CarsonLF , MayerAR , CopelandLJ . Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecologic Oncology1997;65(2):325‐9. ">Carlson 1997</a>; <a href="./references#CD007107-bbs2-0018" title="CullenM , StevenN , BillinghamL , GauntC , HastingsM , SimmondsP , et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine2005;353(10):988‐98. ">Cullen 2005</a>; <a href="./references#CD007107-bbs2-0020" title="DickgreberN , NagelS , RoscherK , SchuetteW . Randomised, placebo‐controlled phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non‐small cell lung cancer: The APRONTA Trial. [19th European Congress of Clinical Microbiology and Infectious Diseases]. Clinical Microbiology and Infection2009;15:S519. ">Dickgreber 2009</a>; <a href="./references#CD007107-bbs2-0042" title="KarpJE , MerzWG , HendricksenC , LaughonB , ReddenT , BambergerBJ , et al. Infection management during antileukemia treatment‐induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. Scandinavian Journal of Infectious Diseases Supplement1986;48:66‐78. ">Karp 1986</a>; <a href="./references#CD007107-bbs2-0047" title="LamyT , MicheletC , DauriacC , GruloisI , DonioPY , PriséPY . Benefit of prophylaxis by intravenous systemic vancomycin in granulocytopenic patients: a prospective, randomized trial among 59 patients. Acta Haematologica1993;90(3):109‐13. ">Lamy 1993</a>; <a href="./references#CD007107-bbs2-0050" title="LeeDG , ChoiSM , ChoiJH , YooJH , ParkYH , KimYJ , et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean Journal of Internal Medicine2002;17(1):38‐44. ">Lee 2002</a>; <a href="./references#CD007107-bbs2-0064" title="PetersenF , ThornquistM , BucknerC , CountsG , NelsonN , MeyersJ , et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection1988;16(4):199‐208. ">Petersen 1988</a>; <a href="./references#CD007107-bbs2-0067" title="PignonB , ThirietL , AubertD , PennaforteJL , VilqueJP , LartigueB , et al. Evaluation of the efficacy of prophylactic intravenous antibiotherapy with ceftriaxone in post‐chemotherapy agranulocytic patients. Nouvelle Revue Française d'Hématologie1990;32(4):249‐52. ">Pignon 1990</a>; <a href="./references#CD007107-bbs2-0070" title="RafecasFJ , GilE , MartínG , MartínezJ , SanzG , SempereA , et al. Oral ciprofloxacin in the prophylaxis of bacterial infection in neutropenic patients. A randomized, double‐blind, comparative clinical study. Revista Española de Quimioterapia1989;2:174‐7. ">Rafecas 1989</a>; <a href="./references#CD007107-bbs2-0073" title="SchuetteW , NagelS , vonWeikersthalLF , PabstS , SchumannC , DeussB , et al. Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non‐small cell lung cancer: the APRONTA trial. Journal of Thoracic Oncology2011;6(12):2090‐6. ">Schuette 2011</a>; <a href="./references#CD007107-bbs2-0078" title="TalbotGH , CassilethPA , ParadisoL , Correa‐CoronasR , BondL . Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrobial Agents &amp; Chemotherapy1993;37(3):474‐82. ">Talbot 1993</a>; <a href="./references#CD007107-bbs2-0080" title="Tjan‐HeijnenVC , CaleoS , PostmusPE , ArdizzoniA , BurghoutsJT , BuccholzE , et al. Economic evaluation of antibiotic prophylaxis in small‐cell lung cancer patients receiving chemotherapy: an EORTC double‐blind placebo‐controlled phase III study (08923). Annals of Oncology2003;14(2):248‐57. ">Tjan‐Heijnen 2003</a>; <a href="./references#CD007107-bbs2-0087" title="YamadaT , DanK , NomuraT . Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Internal Medicine (Tokyo, Japan)1993;32(9):710‐5. ">Yamada 1993</a>). </p> </li> <li> <p>46 trials compared antibiotics and G‐CSF or GM‐CSF to antibiotics only (<a href="./references#CD007107-bbs2-0003" title="AartsMJ , PetersFP , MandigersCM , DercksenMW , StouthardJM , NortierHJ , et al. Primary granulocyte colony‐stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. Journal of Clinical Oncology2013;31(34):4290‐6. [DOI: 10.1200/JCO.2012.44.6229.] ">Aarts 2013</a>; <a href="./references#CD007107-bbs2-0004" title="AlonzoTA , KobrinskyNL , AledoA , LangeBJ , BuxtonAB , WoodsWG . Impact of granulocyte colony‐stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. Journal of Pediatric Hematology/Oncology2002;24(8):627‐35. ">Alonzo 2002</a>; <a href="./references#CD007107-bbs2-0005" title="AltmanA , SteinherzP , TriggM , HalpernS , JhanwarS , PietersR , et al. A prospective randomized trial of granulocyte colony‐stimulating factor (G‐CSF) during induction or consolidation phases of intensive chemotherapy for acute lymphocytic leukemia (ALL) [abstract]. Journal of Clinical Oncology. 1996:542, Abstract 1760. ">Altman 1996</a>; <a href="./references#CD007107-bbs2-0006" title="ArdizzoniA , VenturiniM , SertoliMR , GiannessiPG , BremaF , DanovaM , et al. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. British Journal of Cancer1994;69(2):385‐91. ">Ardizzoni 1994</a>; <a href="./references#CD007107-bbs2-0009" title="BishopMR , TarantoloSR , GellerRB , LynchJC , BiermanPJ , PavleticZS , et al. A randomized, double‐blind trial of filgrastim (granulocyte colony‐stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood2000;96(1):80‐5. ">Bishop 2000</a>; <a href="./references#CD007107-bbs2-0011" title="BradstockK , MatthewsJ , YoungG , LowenthalR , BaxterH , CetalA . Effects of glycosylated recombinant human granulocyte colony‐stimulating factor after high‐dose cytarabine‐based induction chemotherapy for adult acute myeloid leukaemia. Leukemia2001;15(9):1331‐8. ">Bradstock 2001</a>; <a href="./references#CD007107-bbs2-0013" title="BurtonC , LinchD , HoskinP , MilliganD , DyerMJ , HancockB , et al. A phase III trial comparing CHOP to PMitCEBO with or without G‐CSF in patients aged 60 plus with aggressive non‐Hodgkin's lymphoma. British Journal of Cancer2006;94(6):806‐13. ">Burton 2006</a>; <a href="./references#CD007107-bbs2-0016" title="ClarkeV , DunstanFD , WebbDK . Granulocyte colony‐stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Medical &amp; Pediatric Oncology1999;32(5):331‐5. ">Clarke 1999</a>; <a href="./references#CD007107-bbs2-0019" title="DibenedettoSP , RagusaR , IppolitoAM , LoNL , DiCataldoA , D'AmicoS , et al. Assessment of the value of treatment with granulocyte colony‐stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. European Journal of Haematology1995;55(2):93‐6. ">Dibenedetto 1995</a>; <a href="./references#CD007107-bbs2-0024" title="ErnstP , BacigalupoA , RingdenO , RuutuT , KolbHJ , LawrinsonS , et al. A phase 3, randomized, placebo‐controlled trial of filgrastim in patients with haematological malignancies undergoing matched‐related allogeneic bone marrow transplantation. Archives of Drug Information2008;1(3):89‐96. ">Ernst 2008</a>; <a href="./references#CD007107-bbs2-0025" title="FaberE , PytlikR , SlabyJ , ZapletalovaJ , KozakT , RaidaL , et al. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma‐‐results of a prospective multicentre controlled trial. European Journal of Haematology2006;77(6):493‐500. ">Faber 2006</a>; <a href="./references#CD007107-bbs2-0028" title="GarciaG . Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high‐dose chemotherapy: Results of a randomized study. Revista Espanola de Quimioterapia2000; Vol. 15:257‐63. ">Garcia 2000</a>; <a href="./references#CD007107-bbs2-0029" title="Garcia‐SaenzJA , MartinM , CasadoA , Perez‐SeguraP , ManriqueI , FloresL , et al. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high‐dose chemotherapy: results of a randomized study. Revista Espanola de Quimioterapia2002;15(3):257‐63. ">Garcia‐Saenz 2002</a>; <a href="./references#CD007107-bbs2-0030" title="GeisslerK , KollerE , HubmannE , NiederwieserD , HinterbergerW , GeisslerD , et al. Granulocyte colony‐stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia‐‐a randomized phase‐III study. Blood1997;90(2):590‐6. ">Geissler 1997</a>; <a href="./references#CD007107-bbs2-0032" title="Gonzalez‐VicentM , MaderoL , SevillaJ , RamirezM , DiazMA . A prospective randomized study of clinical and economic consequences of using G‐CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation2004;34(12):1077‐81. ">Gonzalez‐Vicent 2004</a>; <a href="./references#CD007107-bbs2-0033" title="GreenbergP , AdvaniR , KeatingA , GulatiSC , NimerS , ChamplinR , et al. GM‐CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation1996;18(6):1057‐64. ">Greenberg 1996</a>; <a href="./references#CD007107-bbs2-0034" title="GulatiSC , BennettCL . Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) as adjunct therapy in relapsed Hodgkin disease. Annals of Internal Medicine1992;116(3):177‐82. ">Gulati 1992</a>; <a href="./references#CD007107-bbs2-0036" title="HeathJA , SteinherzPG , AltmanA , SatherH , JhanwarS , HalpernS , et al. Human granulocyte colony‐stimulating factor in children with high‐risk acute lymphoblastic leukemia: a Children's Cancer Group Study. Journal of Clinical Oncology2003;21(8):1612‐7. ">Heath 2003</a>; <a href="./references#CD007107-bbs2-0037" title="HechtJR , PillaiM , GollardR , HeimW , SwanF , PatelR , et al. A randomized, placebo‐controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every‐2‐week chemotherapy. Clinical Colorectal Cancer2010;9(2):95‐101. ">Hecht 2010</a>; <a href="./references#CD007107-bbs2-0038" title="HeilG , HoelzerD , SanzMA , LechnerK , Liu YinJA , PapaG , et al. A randomized, double‐blind, placebo‐controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood1997;90(12):4710‐8. ">Heil 1997</a>; <a href="./references#CD007107-bbs2-0041" title="JoshiSS , BishopMR , LynchJC , TarantoloSR , AbhyankarS , BiermanPJ , et al. Immunological and clinical effects of post‐transplant G‐CSF versus placebo in T‐cell replete allogeneic blood transplant patients: results from a randomized double‐blind study. Cytotherapy2003;5(6):542‐52. ">Joshi 2003</a>; <a href="./references#CD007107-bbs2-0045" title="LadensteinR , Valteau‐CouanetD , BrockP , YanivI , CastelV , LaureysG , et al. Randomized Trial of prophylactic granulocyte colony‐stimulating factor during rapid COJEC induction in pediatric patients with high‐risk neuroblastoma: the European HR‐NBL1/SIOPEN study. Journal of Clinical Oncology2010;28(21):3516‐24. ">Ladenstein 2010</a>; <a href="./references#CD007107-bbs2-0049" title="LeeSM , RadfordJA , DobsonL , HuqT , RyderWD , PettengellRetal . Recombinant human granulocyte colony‐stimulating factor (filgrastim) following high‐dose chemotherapy and peripheral blood progenitor cell rescue in high‐grade non‐Hodgkin's lymphoma: clinical benefits at no extra cost. British Journal of Cancer1998;77(8):1294‐9. ">Lee 1998</a>; <a href="./references#CD007107-bbs2-0051" title="LehrnbecherT , ZimmermannM , ReinhardtD , DworzakM , StaryJ , CreutzigU . Prophylactic human granulocyte colony‐stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood2007;109(3):936‐43. ">Lehrnbecher 2007</a>; <a href="./references#CD007107-bbs2-0052" title="LittleMA , MorlandB , ChisholmJ , HoleA , ShankarA , DevineT , et al. A randomised study of prophylactic G‐CSF following MRC UKALL XI intensification regimen in childhood ALL and T‐NHL. Medical &amp; Pediatric Oncology2002;38(2):98‐103. ">Little 2002</a>; <a href="./references#CD007107-bbs2-0053" title="MaicheAG , MuhonenT . Granulocyte colony‐stimulating factor (G‐CSF) with or without a quinolone in the prevention of infection in cancer patients. European Journal of Cancer1993;29A(10):1403‐5. ">Maiche 1993</a>; <a href="./references#CD007107-bbs2-0054" title="McQuakerIG , HunterAE , PaceyS , HaynesAP , IqbalA , RussellNH . Low‐dose filgrastim significantly enhances neutrophil recovery following autologous peripheral‐blood stem‐cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit (Structured abstract). Journal of Clinical Oncology1997;15(2):451‐7. ">McQuaker 1997</a>; <a href="./references#CD007107-bbs2-0055" title="MichelG , Landman‐ParkerJ , AuclercMF , MatheyC , LeblancT , LegallE , et al. Use of recombinant human granulocyte colony‐stimulating factor to increase chemotherapy dose‐intensity: a randomized trial in very high‐risk childhood acute lymphoblastic leukemia. Journal of Clinical Oncology2000;18(7):1517‐24. ">Michel 2000</a>; <a href="./references#CD007107-bbs2-0057" title="MilesDW , FogartyO , AshCM , RuddRM , TraskCW , SpiroSG , et al. Received dose‐intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony‐stimulating factor in small‐cell lung cancer. Journal of Clinical Oncology1994;12(1):77‐82. ">Miles 1994</a>; <a href="./references#CD007107-bbs2-0058" title="NemunaitisJ , RosenfeldCS , AshR , FreedmanMH , DeegHJ , AppelbaumF , et al. Phase III randomized, double‐blind placebo‐controlled trial of rhGM‐CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation1995;15(6):949‐54. ">Nemunaitis 1995</a>; <a href="./references#CD007107-bbs2-0059" title="NolanL , LoriganP , ChiltonS , NewmanJ , ElseR , SmithP , et al. Low‐dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. British Journal of Haematology2007;137(5):436‐42. ">Nolan 2007</a>; <a href="./references#CD007107-bbs2-0060" title="OjedaE , Garcia‐BustosJ , AguadoM , ArrietaR , QuevedoE , YusteVJ , et al. A prospective randomized trial of granulocyte colony‐stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplantation1999;24(6):601‐7. ">Ojeda 1999</a>; <a href="./references#CD007107-bbs2-0062" title="OttmannOG , HoelzerD , GracienE , GanserA , KellyK , ReutzelR , et al. Concomitant granulocyte colony‐stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood1995;86(2):444‐50. ">Ottmann 1995</a>; <a href="./references#CD007107-bbs2-0065" title="PettengellR , GurneyH , RadfordJA , DeakinDP , JamesR , WilkinsonPM , et al. Granulocyte colony‐stimulating factor to prevent dose‐limiting neutropenia in non‐Hodgkin's lymphoma: a randomized controlled trial. Blood1992;80(6):1430‐6. ">Pettengell 1992</a>; <a href="./references#CD007107-bbs2-0066" title="PiccirilloN , SicaS , LaurentiL , ChiusoloP , LaBarberaEO , SoraF , et al. Optimal timing of G‐CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplantation1999;23(12):1245‐50. ">Piccirillo 1999</a>; <a href="./references#CD007107-bbs2-0068" title="PrzepiorkaD , SmithTL , FolloderJ , AnderliniP , ChanKW , KorblingM , et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen‐matched related donors. Blood2001;97(11):3405‐10. ">Przepiorka 2001</a>; <a href="./references#CD007107-bbs2-0069" title="PuiCH , BoyettJM , HughesWT , RiveraGK , HancockML , SandlundJT , et al. Human granulocyte colony‐stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New England Journal of Medicine1997;336(25):1781‐7. ">Pui 1997</a>; <a href="./references#CD007107-bbs2-0072" title="SchmitzN , LjungmanP , CordonnierC , KempfC , LinkeschW , AlegreA , et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double‐blind, randomized trial. Bone Marrow Transplantation2004;34(11):955‐62. ">Schmitz 2004</a>; <a href="./references#CD007107-bbs2-0075" title="SpitzerG , AdkinsDR , SpencerV , DunphyFR , PetruskaPJ , VelasquezWS , et al. Randomized study of growth factors post‐peripheral‐blood stem‐cell transplant: neutrophil recovery is improved with modest clinical benefit. Journal of Clinical Oncology1994;12(4):661‐70. ">Spitzer 1994</a>; <a href="./references#CD007107-bbs2-0076" title="StahelRA , JostLM , CernyT , PichertG , HoneggerH , ToblerA , et al. Randomized study of recombinant human granulocyte colony‐stimulating factor after high‐dose chemotherapy and autologous bone marrow transplantation for high‐risk lymphoid malignancies. Journal of Clinical Oncology1994;12(9):1931‐8. ">Stahel 1994</a>; <a href="./references#CD007107-bbs2-0079" title="Timmer‐BonteJN , deBooTM , SmitHJ , BiesmaB , WilschutFA , CheragwandiSA , et al. Prevention of chemotherapy‐induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony‐stimulating factor in small‐cell lung cancer: a Dutch Randomized Phase III Study. Journal of Clinical Oncology2005;23(31):7974‐84. ">Timmer‐Bonte 2005</a>; <a href="./references#CD007107-bbs2-0081" title="TriggME , PetersC , ZimmermanMB . Administration of recombinant human granulocyte‐macrophage colony‐stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double‐masked, placebo‐controlled trial. Pediatric Transplantation2000;4(2):123‐31. ">Trigg 2000</a>; <a href="./references#CD007107-bbs2-0085" title="WelteK , ReiterA , MempelK , PfetschM , SchwabG , SchrappeM , et al. A randomized phase‐III study of the efficacy of granulocyte colony‐stimulating factor in children with high‐risk acute lymphoblastic leukemia. Berlin‐Frankfurt‐Munster Study Group. Blood1996;87(8):3143‐50. ">Welte 1996</a>; <a href="./references#CD007107-bbs2-0086" title="WitzF , SadounA , PerrinMC , BerthouC , BriereJ , CahnJY , et al. A placebo‐controlled study of recombinant human granulocyte‐macrophage colony‐stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood1998;91(8):2722‐30. ">Witz 1998</a>; <a href="./references#CD007107-bbs2-0088" title="YauJC , NeidhartJA , TriozziP , VermaS , NemunaitisJ , QuickDP , et al. Randomized placebo‐controlled trial of granulocyte‐macrophage colony‐stimulating‐factor support for dose‐intensive cyclophosphamide, etoposide, and cisplatin. American Journal of Hematology1996;51(4):289‐95. ">Yau 1996</a>; Zinzani 1997a). </p> </li> <li> <p>7 trials compared antibiotics and G‐CSF to G‐CSF only (<a href="./references#CD007107-bbs2-0023" title="Eleutherakis‐PapaiakovouE , KostisE , MigkouM , ChristoulasD , TerposE , GavriatopoulouM , et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: results of a single institution, randomized phase 2 trial. American Journal of Hematology2010;85(11):863‐7. ">Eleutherakis‐Papaiakovou 2010</a>; <a href="./references#CD007107-bbs2-0026" title="FengX , RuanY , HeY , ZhangY , WuX , LiuH , et al. Prophylactic first‐line antibiotics reduce infectious fever and shorten hospital stay during chemotherapy‐induced agranulocytosis in childhood acute myeloid leukemia. Acta Haematologica2014;132(1):112‐7. ">Feng 2014</a>; <a href="./references#CD007107-bbs2-0043" title="KimS , ChoYH , KoOB , KooJE , LeeD , ChongYP , et al. Beneficial prophylactic antimicrobial use against infectious complications during autologous stem cell transplantation: a result of randomized phase II study in multiple myeloma and non‐Hodgkin's lymphoma patients. Blood. 2005; Vol. 11. ">Kim 2005</a>; <a href="./references#CD007107-bbs2-0046" title="LalamiY , PaesmansM , AounM , Munoz‐BermeoR , ReussK , CherifiS , et al. A prospective randomised evaluation of G‐CSF or G‐CSF plus oral antibiotics in chemotherapy‐treated patients at high risk of developing febrile neutropenia. Supportive Care in Cancer2004;12(10):725‐30. ">Lalami 2004</a>; <a href="./references#CD007107-bbs2-0049" title="LeeSM , RadfordJA , DobsonL , HuqT , RyderWD , PettengellRetal . Recombinant human granulocyte colony‐stimulating factor (filgrastim) following high‐dose chemotherapy and peripheral blood progenitor cell rescue in high‐grade non‐Hodgkin's lymphoma: clinical benefits at no extra cost. British Journal of Cancer1998;77(8):1294‐9. ">Lee 1998</a>; <a href="./references#CD007107-bbs2-0077" title="SuhY , ChunC , OhS . Prevention of infection after TAC chemotherapy for node‐positive breast cancer as an adjuvant therapy with or without ciprofloxacin. Annals of Oncology2008;26(15S):81. ">Suh 2008</a>; <a href="./references#CD007107-bbs2-0080" title="Tjan‐HeijnenVC , CaleoS , PostmusPE , ArdizzoniA , BurghoutsJT , BuccholzE , et al. Economic evaluation of antibiotic prophylaxis in small‐cell lung cancer patients receiving chemotherapy: an EORTC double‐blind placebo‐controlled phase III study (08923). Annals of Oncology2003;14(2):248‐57. ">Tjan‐Heijnen 2003</a>). </p> </li> <li> <p>21 trials compared G‐CSF to placebo or no further treatment (<a href="./references#CD007107-bbs2-0008" title="BennettCL , HynesD , GodwinJ , StinsonTJ , GolubRM , AppelbaumFR , et al. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Investigation2001;19(6):603‐10. ">Bennett 2001</a>; <a href="./references#CD007107-bbs2-0010" title="BjörkholmM , OsbyE , HagbergH , KvaloyS , TeerenhoviL , MyhreJ . Randomized trial of r‐metHu granulocyte colony‐stimulating factor (G‐CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non‐Hodgkin's lymphoma [abstract]. Blood. 1999:599a. ">Björkholm 1999</a>; <a href="./references#CD007107-bbs2-0012" title="BruggerW , BaconP , LawrinsonS , RomieuG . Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline‐containing chemotherapy with pegfilgrastim support. Critical Reviews in Oncology/Hematology2009;72(3):265‐9. ">Brugger 2009</a>; <a href="./references#CD007107-bbs2-0015" title="ChevallierB , CholletP , MerroucheY , RocheH , FumoleauP , KerbratP , et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. Journal of Clinical Oncology1995;13(7):1564‐71. ">Chevallier 1995</a>; <a href="./references#CD007107-bbs2-0017" title="CrawfordJ , KreismanH , GarewalH , JonesSE , ShoemakerD , PupaMR , et al. The impact of filgrastim schedule variation on hematopoietic recovery post‐chemotherapy. Annals of Oncology1997;8(11):1117‐24. ">Crawford 1997</a>; <a href="./references#CD007107-bbs2-0021" title="DoorduijnJ , BuijtI , HoltB , SteijaertM , Uyl‐de GrootC , SonneveldP . Self‐reported quality of life in elderly patients with aggressive non‐Hodgkin's lymphoma treated with CHOP chemotherapy. European Journal of Haematology2005;75(2):116‐23. ">Doorduijn 2005</a>; <a href="./references#CD007107-bbs2-0022" title="DunlopDJ , AndersenS , PaulJ , SoukopM , EllisD , TanseyP . Filgrastim as an adjunct to combination chemotherapy in Hodgkin's disease. Annals of Oncology1996:51. ">Dunlop 1996</a>; <a href="./references#CD007107-bbs2-0027" title="FridrikMA , GreilR , HausmaningerH , KriegerO , OppitzP , StogerM , et al. Randomized open label phase III trial of CEOP/IMVP‐Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP‐Dexa alternating chemotherapy for aggressive non‐Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.[Erratum appears in Ann Hematol. 2014 Mar;93(3):539‐40]. Annals of Hematology1997;75(4):135‐40. ">Fridrik 1997</a>; <a href="./references#CD007107-bbs2-0031" title="GodwinJE , KopeckyKJ , HeadDR , WillmanCL , LeithCP , HynesHE , et al. A double‐blind placebo‐controlled trial of granulocyte colony‐stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood1998;91(10):3607‐15. ">Godwin 1998</a>; <a href="./references#CD007107-bbs2-0035" title="HartmannLC , TschetterLK , HabermannTM , EbbertLP , JohnsonPS , MailliardJA , et al. Granulocyte colony‐stimulating factor in severe chemotherapy‐induced afebrile neutropenia. New England Journal of Medicine1997;336(25):1776‐80. ">Hartmann 1997</a>; <a href="./references#CD007107-bbs2-0039" title="HolowieckiJ , GiebelS , KrzemienS , Krawczyk‐KulisM , JagodaK , KoperaM , et al. G‐CSF administered in time‐sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long‐term outcome: a randomized multicenter study. Leukemia &amp; Lymphoma2002;43(2):315‐25. ">Holowiecki 2002</a>; <a href="./references#CD007107-bbs2-0044" title="KosakaY , RaiY , MasudaN , TakanoT , SaekiT , NakamuraS , et al. Phase III placebo‐controlled, double‐blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer2015;23(4):1137‐43. ">Kosaka 2015</a>; <a href="./references#CD007107-bbs2-0048" title="LarsonRA , DodgeRK , LinkerCA , StoneRM , PowellBL , LeeEJ , et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood1998;92(5):1556‐64. ">Larson 1998</a>; <a href="./references#CD007107-bbs2-0056" title="MichonJM , HartmannO , BouffetE , MeresseV , CozeC , RubieH , et al. An open‐label, multicentre, randomised phase 2 study of recombinant human granulocyte colony‐stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. European Journal of Cancer1998;34(7):1063‐9. ">Michon 1998</a>; <a href="./references#CD007107-bbs2-0061" title="OsbyE , HagbergH , KvaløyS , TeerenhoviL , AndersonH , Cavallin‐StahlE , et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood2003;101(10):3840‐8. ">Osby 2003</a>; <a href="./references#CD007107-bbs2-0063" title="PatteC , LaplancheA , BertozziAI , BaruchelA , FrappazD , SchmittC , et al. Granulocyte colony‐stimulating factor in induction treatment of children with non‐Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. Journal of Clinical Oncology2002;20(2):441‐8. ">Patte 2002</a>; <a href="./references#CD007107-bbs2-0071" title="RomieuG , ClemensM , MahlbergR , FargeotP , ConstenlaM , SchutteM , et al. Pegfilgrastim supports delivery of FEC‐100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Critical Reviews in Oncology/hematology2007;64(1):64‐72. ">Romieu 2007</a>; <a href="./references#CD007107-bbs2-0074" title="SeymourAM , deCamposE , ThatcherN , DeGreveJ , CunninghamD , HowellA , et al. A single‐blind, randomised, vehicle‐controlled dose‐finding study of recombinant human granulocyte colony‐stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. European Journal of Cancer1995;31A(13‐14):2157‐63. ">Seymour 1995</a>; <a href="./references#CD007107-bbs2-0082" title="Trillet‐LenoirV , GreenJ , ManegoldC , VonPawelJ , GatzemeierU , LebeauB , et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer1993;29A(3):319‐24. ">Trillet‐Lenoir 1993</a>; <a href="./references#CD007107-bbs2-0083" title="VeyretC , LevyC , CholletP , MerroucheY , RocheH , KerbratP , et al. Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy: ten‐year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer2006;107(11):2535‐44. ">Veyret 2006</a>; <a href="./references#CD007107-bbs2-0084" title="VogelCL , WojtukiewiczMZ , CarrollRR , TjulandinSA , Barajas‐FigueroaLJ , WiensBL , et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2005;23(6):1178‐84. ">Vogel 2005</a>). </p> </li> </ul> </p> </section> </section> <section id="CD007107-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD007107-fig-0002">Figure 2</a> and <a href="#CD007107-fig-0003">Figure 3</a> for risk of bias summary. </p> <div class="figure" id="CD007107-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007107-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007107-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007107-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD007107-sec-0069"> <h4 class="title">Allocation</h4> <p>Both trials were described as randomised, but the randomisation procedure was not reported. Therefore, we judged the risk of selection bias as unclear. </p> </section> <section id="CD007107-sec-0070"> <h4 class="title">Blinding</h4> <p>There was no blinding of the participants or personnel due to the use of either an oral antibiotic or subcutaneous injections of GM‐CSF; no information was given about whether or not the assessors were blinded. Therefore we judged potential risk of performance bias as high and of detection bias as unclear. </p> </section> <section id="CD007107-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>As 23 courses from seven patients from the antibiotics group, who switched to rhG‐CSF, were not included in the analysis by <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a>, we judged the risk of attrition bias as high in this trial. All patients in the <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> trial were evaluated as randomised, reasons for ten patients not being eligible after randomisation were given. Therefore, we judged risk of attrition bias for this trial as low. </p> </section> <section id="CD007107-sec-0072"> <h4 class="title">Selective reporting</h4> <p>As we did not identify study protocols; it is unclear if all the planned outcomes are reported. We judged the risk of reporting bias as unclear. </p> </section> <section id="CD007107-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>As no other potential source of bias was reported, we judged this bias as "unclear".</p> </section> </section> <section id="CD007107-sec-0074"> <h3 class="title" id="CD007107-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD007107-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD007107-tbl-0002"><b>Summary of findings 2</b> </a> </p> <section id="CD007107-sec-0075"> <h4 class="title">Comparison 1: G‐CSF versus antibiotics</h4> <section id="CD007107-sec-0076"> <h5 class="title">Overall survival</h5> <p>Not reported by <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a>. </p> </section> <section id="CD007107-sec-0077"> <h5 class="title">All cause mortality (including infection‐related, treatment‐related, or on‐trial mortality)</h5> <p>Not reported by <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a>. </p> </section> <section id="CD007107-sec-0078"> <h5 class="title">Infection‐related mortality</h5> <p>Infection‐related mortality was the same in both groups of the <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> trial: no patient died of infectious causes during the 18‐week duration of the trial. </p> </section> <section id="CD007107-sec-0079"> <h5 class="title">Microbiologically or clinically documented infections</h5> <p>Not reported.</p> </section> <section id="CD007107-sec-0080"> <h5 class="title">Incidence of severe infections</h5> <p>Not reported</p> </section> <section id="CD007107-sec-0081"> <h5 class="title">Quality of life (QoL)</h5> <p>Not reported.</p> </section> <section id="CD007107-sec-0082"> <h5 class="title">Incidence of febrile neutropenia (FN)</h5> <p><a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> reported febrile neutropenia in 7/18 patients receiving G‐CSF and in 7/22 patients receiving ciprofloxacin and amphotericin B (relative risk (RR) 1.22; 95% confidence interval (CI) 0.53 to 2.84). </p> </section> <section id="CD007107-sec-0083"> <h5 class="title">Adverse events</h5> <p>Not reported.</p> </section> </section> <section id="CD007107-sec-0084"> <h4 class="title">Comparison 2: GM‐CSF versus antibiotics</h4> <section id="CD007107-sec-0085"> <h5 class="title">Overall survival</h5> <p>There was no evidence of a difference in median survival time, with 264 (95% CI 220 to 308) days for patients in the GM‐CSF arm and 264 (95% CI 223 to 305 days) in the antibiotics arm (<a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a>). Two‐year survival times were 6% (0 to 12%) in both arms. </p> </section> <section id="CD007107-sec-0086"> <h5 class="title">All cause mortality (including infection‐related, treatment‐related, or on‐trial mortality)</h5> <p>There were four toxic deaths in the GM‐CSF arm (5.1%) and three in the antibiotics arm (3.8%), without evidence for a difference (RR 1.32; 95% CI 0.30 to 5.69; P = 0.71). </p> </section> <section id="CD007107-sec-0087"> <h5 class="title">Infection‐related mortality</h5> <p>This outcome was not reported in <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a>. </p> </section> <section id="CD007107-sec-0088"> <h5 class="title">Microbiologically or clinically documented infections</h5> <p>There were 22 grade III or IV infections (28%) in the GM‐CSF arm in the <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> trial and 14 infections (18%) in the antibiotics arm, without any evidence of a difference (RR 1.55; 95% CI 0.86 to 2.80; P = 0.15). </p> </section> <section id="CD007107-sec-0089"> <h5 class="title">Incidence of severe infections</h5> <p>There were 5 episodes out of 360 cycles (1.3%) of grade IV infections in the GM‐CSF arm and 3 episodes out of 334 cycles in the cotrimoxazole arm (0.8%), without evidence of a difference (RR 1.55; 95% CI 0.37 to 6.42; P = 0.55). </p> </section> <section id="CD007107-sec-0090"> <h5 class="title">Quality of life (QoL)</h5> <p>Not reported.</p> </section> <section id="CD007107-sec-0091"> <h5 class="title">Incidence of febrile neutropenia (FN)</h5> <p>Not reported.</p> </section> <section id="CD007107-sec-0092"> <h5 class="title">Adverse events</h5> <p>There was no significant difference between the two arms for non‐haematological toxicities like diarrhoea, stomatitis, infections, neurologic, respiratory or cardiac adverse events. Grade III and IV thrombopenia occurred significantly more frequently in the GM‐CSF arm (60.8%) compared to the antibiotics arm (28.9%); with a RR 2.10; 95% CI 1.41 to 3.12; P = 0.0002. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007107-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007107-sec-0093"></div> <section id="CD007107-sec-0094"> <h3 class="title" id="CD007107-sec-0094">Summary of main results</h3> <p>The striking finding of this review is that there is only one very small study comparing granulocyte colony‐stimulating factors (G‐CSF) to antibiotics for infection prophylaxis in cancer patients receiving myelosuppressive chemotherapy, and one trial with 155 patients evaluating granulocyte macrophage colony‐stimulating factors (GM‐CSF) versus antibiotics. The trial evaluating G‐CSF did not report all cause mortality, incidence of documented or severe infections, quality of life, or adverse events. We did not find evidence of a difference in infection‐related mortality (none of the 40 included patients died because of infection), or in incidence of febrile neutropenia. </p> <p>The trial that evaluated GM‐CSF reported overall survival, toxic deaths, infections and severe infections and non‐haematological adverse events, without any evidence of a difference between the GM‐CSF arm and the antibiotics arm. Patients in the antibiotics arm had fewer thrombopenic adverse events. Quality of life was not reported. </p> </section> <section id="CD007107-sec-0095"> <h3 class="title" id="CD007107-sec-0095">Overall completeness and applicability of evidence</h3> <p>As only two small trials were identified, it is not possible to come to a final conclusion regarding the best prophylactic regimen in cancer patients at risk of neutropenia. Therefore, this clinically important question remains unanswered. Moreover, the trial assessing G‐CSF evaluated only a few of the outcomes of interest (incidence of febrile neutropenia and infection‐related mortality), but all cause mortality, incidence of documented or severe infections, quality of life, and adverse events were not assessed. </p> <p>The trial evaluating GM‐CSF versus antibiotics reported more of the outcomes of interest (overall survival, toxic deaths, infections and severe infections and adverse events), however, due to the small sample size, there was no evidence of a difference, except for the adverse event, thrombocytopenia. </p> <p>The 41 trials that were excluded because they evaluated the influence of the combination of GM‐CSF and antibiotics compared to GM‐CSF or antibiotics only, underline the huge imbalance between the number of direct comparisons of the two drugs we evaluated in this review, and the number of trials that were conducted in this field. </p> </section> <section id="CD007107-sec-0096"> <h3 class="title" id="CD007107-sec-0096">Quality of the evidence</h3> <p>The risk of bias in <a href="./references#CD007107-bbs2-0001" title="SchroderCP , deVriesEG , MulderNH , WillemsePH , SleijferDT , HospersGA , et al. Prevention of febrile leucopenia after chemotherapy in high‐risk breast cancer patients: no significant difference between granulocyte‐colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy1999;43(5):741‐3. ">Schroder 1999</a> was high, as this trial was not blinded and not all patients of the included 40 patients were analysed as randomised (seven of 22 patients from the antibiotics arm crossed‐over to G‐CSF and were excluded from analysis). The risk of bias for <a href="./references#CD007107-bbs2-0002" title="SculierJP , PaesmansM , LecomteJ , VanCutsemO , LafitteJJ , BerghmansT , et al. A three‐arm phase III randomised trial assessing, in patients with extensive‐disease small‐cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer2001;85(10):1444‐51. ">Sculier 2001</a> could be considered to be moderate, as risk of performance bias was high, but risk of selection and attrition bias was low. </p> <p>As only two trials could be included in this review, one evaluating G‐CSF, the other evaluating GM‐CSF, no meta‐analysis was possible.The trial evaluating G‐CSF reported infection‐related mortality and incidence of febrile neutropenia. We judged the quality of evidence for both outcomes to be very low, due to the small number of events, which lead to high imprecision (downgraded by two levels), and the high risk of bias (downgraded by one level). </p> <p>The trial that analysed GM‐CSF versus antibiotics reported overall survival, toxic deaths, infections, severe infections and adverse events. Because of the very small number of patients included, we downgraded overall quality of the evidence for all outcomes by two levels (high imprecision). As risk of bias was moderate in this trial, we did not downgrade the quality of evidence for this reason. Therefore, overall quality for all the outcomes mentioned above was considered to be low. </p> </section> <section id="CD007107-sec-0097"> <h3 class="title" id="CD007107-sec-0097">Potential biases in the review process</h3> <p>To prevent bias within the review, we considered only RCTs and performed all relevant processes in duplicate. We developed a sensitive search strategy, and searched all relevant data from international cancer congresses by hand to minimise potential publication bias. We are not aware of any obvious deficiencies in our review process. The small number of trials included in this review could lead to publication bias as a funnel plot could not be generated. </p> </section> <section id="CD007107-sec-0098"> <h3 class="title" id="CD007107-sec-0098">Agreements and disagreements with other studies or reviews</h3> <p>One comprehensive meta‐analysis of GM‐CSF versus control includes 148 trials with more than 16,000 patients (<a href="./references#CD007107-bbs2-0131" title="SungL , NathanPC , AlibhaiSM , TomlinsonGA , BeyeneJ . Meta‐analysis: effect of prophylactic hematopoietic colony‐stimulating factors on mortality and outcomes of infection. Annals of Internal Medicine2007;147(6):400‐11. ">Sung 2007</a>). However, in this publication it is not reported how many patients received additional antibiotics, and how many patients received either G‐CSF or GM‐CSF. Similarly, the most comprehensive antibiotics versus control meta‐analysis includes 49 trials with more than 6000 patients (for the outcome all cause mortality; <a href="./references#CD007107-bbs2-0104" title="Gafter‐GviliA , FraserA , PaulM , LeiboviciL . Meta‐Analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of Internal Medicine2005;142(12 Pt 1):979‐95. ">Gafter‐Gvili 2005</a>). The low number of trials directly comparing antibiotics to G‐CSFs is surprising, considering the higher cost of GM‐CSFs compared to standard antibiotics. However, a high number of trials comparing GM‐CSFs to control received funding from pharmaceutical companies that produce GM‐CSFs. As there are only two small trials directly comparing G‐CSF or GM‐CSF versus antibiotics, no final conclusion on the best prophylactic regimen is possible. Clearly, more trials with larger numbers of patients are required to answer this question, in particular, with regard to early all cause and infection‐related mortality. In addition, GM‐CSF is no longer commercially available for infection prophylaxis in several European countries; it is licensed instead for mobilisation of stem cells or after autologous or allogeneic stem cell transplantation (<a href="./references#CD007107-bbs2-0127" title="SmithTJ , BohlkeK , LymanGH , CarsonKR , CrawfordJ , CrossSJ , et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology2015;33(28):3199‐212. ">Smith 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007107-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/urn:x-wiley:14651858:media:CD007107:CD007107-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_t/tCD007107-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007107-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007107-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/urn:x-wiley:14651858:media:CD007107:CD007107-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_t/tCD007107-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007107-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007107-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/urn:x-wiley:14651858:media:CD007107:CD007107-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_t/tCD007107-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007107-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/media/CDSR/CD007107/image_n/nCD007107-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007107-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>G‐CSF compared with antibiotics</b> f<b>or the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cancer patients receiving myelotoxic chemotherapy </p> <p><b>Intervention:</b> G‐CSF </p> <p><b>Comparison:</b> antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>G‐CSF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,2</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no patient died of infectious causes during the 18‐week duration of the trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of febrile neutropenia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>318 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>388 per 1000</b> </p> <p>(169 to 904)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.22</b> </p> <p>(0.53 to 2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>1,2</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of severe infections</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> due to the low number of very low number of events, the result is highly imprecise (downgraded by 2 points) </p> <p><sup>2</sup> high risk of performance bias (neither patients nor physicians blinded) and detection bias (no intention to treat analysis) (downgraded by 1 point) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007107-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GM‐CSF compared with antibiotics</b> f<b>or the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cancer patients receiving myelotoxic chemotherapy </p> <p><b>Intervention:</b> GM‐CSF </p> <p><b>Comparison:</b> antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>GM‐CSF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All cause mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<sup>1</sup> <br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two‐year survival times were 6% (0 to 12%) in both arms</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infection‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of febrile neutropenia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence of severe infections</p> <p>(Grade III or IV)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>282 per 1000</b> </p> <p>(156 to 509)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.55</b> </p> <p>(0.86 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<sup>1</sup> <br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>Toxic deaths</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> <p>(12 to 222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> </p> <p>(0.30 to 5.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1</sup> <br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> due to the low number of very low number of events, the result is highly imprecise (downgraded by 2 points) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007107.pub3/full#CD007107-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007107.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007107-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007107-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007107-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="th#CD007107-note-0006">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007107\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007107\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007107\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007107\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007107\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007107.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007107.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007107.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007107.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007107.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728368787"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007107.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728368791"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007107.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec2ca69929367',t:'MTc0MDcyODM2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 